Maddie Whoriskey is a college student at Yale University who assists with administrative tasks at Concarlo.

Anusha serves as a Principal Scientist at Concarlo. Anusha is a Biotechnologist with a specialization in developing peptide-based organic/inorganic nanomedicine platforms for drug delivery and gene delivery applications. Anusha received her Ph.D. at the Council for Scientific and Industrial Research (CSIR), New Delhi, India, in 2018. Following that, Anusha did her postdoctoral research at the Indian Institute of Technology, Delhi (IIT-Delhi), India, with Dr. Archana Chugh, and at Memorial Sloan Kettering Cancer Centre, New York, with Dr. Michelle Bradbury. During Anusha’s doctoral and postdoctoral studies, she designed various nanoparticle assemblies for anti-cancer and antimicrobial applications.

Lena serves as a Research Scientist at Concarlo. Lena obtained her BS from NYU Tandon School of Engineering in biomolecular science with a minor in psychology. Lena has experience in a variety of labs at top institutions, specializing in immuno-oncology and molecular biology. Lena has performed basic and high-skill techniques for both in vivo and in vitro experiments in both academic and industry settings. Lena is highly motivated and passionate about oncology research.

Skylar serves as a Business Development and Research intern at Concarlo. Skylar is an undergraduate student at the University of Pennsylvania studying Bioengineering with a concentration in Biomedical Devices and a minor in Entrepreneurship. In addition, Skylar has research experience in cancer systems biology, genetic engineering, and neuroengineering for traumatic brain injury.

Dr. Bridon is an R&D executive with extensive North American and international experience of drug development from research to proof-of-concept clinical studies (Phase II) and regulatory submission in EU and US. 20+ years of experience with peptides therapeutics including drug protein bio-conjugate development across multiple therapeutic areas to treat cancer, anti-infective, metabolic and cardiovascular diseases. He previously held various management positions at Optivia (acquired by BioIVT), Ipsen, Abbott, Enobia (acquired by Alexion) and Neuronax and served on the scientific boards of Syntaxin (acquired by Ipsen) and Biosortia. He is currently CEO of Diaccurate, a Paris-based star-up.

Ms. Matz, RPh, is a seasoned, results oriented pharmaceutical professional providing technical consulting in the areas of product formulation and process development for preclinical through Phase 4 studies. Her expertise encompasses the preparation and manufacture of a myriad of delivery systems including tablets (IR, MR and ER, orally disintegrating and thin films), capsules (hard and soft shell), spray dried and dispersed systems, liquids (solutions, micro emulsions, suspensions and nasogastric enteral systems), transdermal drug delivery systems, topicals (ointments, creams and sticks), MDI’s, DPI’s, suppositories, etc. She also has extensive experience in conducting process scale-up and validation; clinical trial material and launch supply manufacturing and packaging; technology transfers; NDA/CTD writing, etc. She has worked with Pfizer, Medivation, Boehringer Ingelheim and Key Pharmaceuticals developing proprietary NME’s as well as having worked with generic companies. Furthermore, she is named on several patents.

Jeff Millard has both academic and industrial experience in chemistry and pharmaceutical sciences covering all aspects of CMC (chemistry, manufacturing, and controls). He has been directly responsible for the research and IND authoring of more than 7 IND submissions (to both CDER and CBER), IMPDs, and several successful SBIR grant applications. His drug product experience includes pre-formulation, formulation, tech transfer and cGMP manufacturing of both solid oral dosages as well as sterile, complex parenterals including liposomes.

Dr. DeVita is an experienced medicinal chemist and drug hunter in academia, biotech and large pharmaceutical environments. He has over 30 years of drug discovery and development experience including expertise managing multi-disciplinary teams to deliver on key program objectives for complex molecular targets. Dr. DeVita started his career at Merck Research Laboratories and rose to Director of Medicinal Chemistry, where he delivered many development candidates and led drug discovery and development teams. Dr. DeVita was also VP of Chemistry at Agios Pharmaceuticals focused on oncology drug discovery. Since 2013, he founded a consulting firm which has consulted for a wide variety of clients including biotechs building translational drug discovery programs. He is also Professor in the Dept. of Pharmacological Sciences and Director of Medicinal Chemistry in the Drug Discovery Institute of Icahn School of Medicine at Mt. Sinai since 2014.

Dr. Janice Lansita is a board-certified toxicologist with over 17 years of experience both in the biopharmaceutical industry and with the Food and Drug Administration (FDA). As a regulatory toxicologist, she has developed small molecule (NME and 505(b)(2)) and biologic therapies for a broad range of indications (e.g., rare disease, oncology, neurology, pain, ophthalmology, and immunology). Dr. Lansita has extensive experience in the design, monitoring, and interpretation of nonclinical toxicology studies (GLP and non-GLP) and has authored the nonclinical sections of various regulatory documents, including pre-INDs, INDs/CTAs (>45), Investigator Brochures, BLAs/NDAs, and package inserts/product labels for biopharmaceuticals.

Dr. Wu is an Associate Professor in the Department of Biomedical Engineering at University at Buffalo, The State University of New York (SUNY Buffalo). Her research focuses on the development of nanotherapeutics for cancer and chronic diseases and the development of in vitro diagnostic tests for cancer screening, diagnosis and prognosis. She received her Ph.D. from the Department of Chemical and Biomolecular Engineering at the Ohio State University in 2009. After completion of her degree, she received her postdoc training in the NSF Nanoscale Science and Engineering Center at the Ohio State University.